



Government of Pakistan  
Ministry of National Health Services, Regulations & Coordination  
Drug Regulatory Authority Of Pakistan  
Health & OTC Products Division (Non-Drugs)  
\*\*\*\*\*

Islamabad, the 24<sup>th</sup> February, 2022

“SAY NO TO CORRUPTION”

**Subject: Submission of deficient information / documents**

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 97<sup>th</sup> meeting held on 13<sup>th</sup> October, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No (1)	Brand name (2)	Decision (3)
<b>(For Export Purpose Only)</b>		
<b>M/s Davis Pharmaceuticals Lab, 121/1, Industrial Triangle Area, Kahuta Road, Islamabad</b>		
1.	Xinkox Ointment	Deferred for clarification the Single ingredient zinc is registered as drug
2.	Xinkox Plus Ointment	Deferred for clarification the Single ingredient zinc is registered as drug
3.	HNS + Tablet	Deferred since the quantity of biotin as above RDA
4.	HealthEase Zinc 10mg Syrup	Deferred for clarification Single ingredient zinc is registered as drug
<b>For Export Facilitation (Local)</b>		
<b>M/s SOIS LIFE SCIENCES, Karachi</b>		
5.	NATALVIT IQ TABLET	Deferred for clarification of RDA of zinc
6.	ALIVE PLUS G TABLET	Deferred for change of brand name
7.	CALRICH SOFT GELATIN CAPSULE	The division has addressed almost all application submitted till 2018, therefore the firm is required to submit fee for this product.
8.	CALRICH SACHET	The division has addressed almost all application submitted till 2018, therefore the firm is required to submit fee for this product
9.	CALRICH SYRUP	The division has addressed almost all application submitted till 2018, therefore the firm is required to submit fee for this product
<b>For Export Facilitation (Local)</b>		
<b>Al-Noor Medica (Pvt.) Ltd.Faislabad</b>		
10.	Sharbat Faulad	Deferred for change of brand name
11.	N-40 Uranium Nitricum Drops	Deferred for clarification of Uranium, since it require stringent regulatory control
<b>For Export Facilitation (Local)</b>		
<b>M/s Dawakhana Hakim Ajmal Khan Pvt limited, Lahore (E. No. 00731)</b>		
12.	Qurs Jiryan Ajmali	Deferred for Clarification of Kushta Qali
13.	Safuf Mudir Khas Ajmali	Deferred for clarification of Ferrous sulfate quantity
<b>M/s Bio-Lab Consumer Health,</b>		
<b>Plot No. 50, Street No. S-10, RCCI Industrial Estate, Rawat</b>		
14.	Bio-Stomach Powder	EEC decided to defer the application for enlistment due to following reasons: The applied product contains sodium bicarbonate which is added in the list of common molecules.
15.	Dextro Plus powder	EEC decided to defer the application for enlistment due to following reasons: Justify the use of Glucose as active ingredient. Clarification is required regarding rationalization of strengths of each active ingredient since the firm is using different salts as a

S.No (1)	Brand name (2)	Decision (3)
		source for specific element e.g. Chloride will be delivered by Calcium chloride, sodium chloride and potassium chloride; & Calcium is being delivered by Calcium chloride and Calcium carbonate.
16.	Bio-VitaAll WSP	EEC decided to defer the application for enlistment due to following reasons: The applied product contains Potassium Bicarbonate which is added in the list of common molecules. Brand name needs to be changed. Clarification is required regarding rationalization of strengths of chloride containing elemental ingredients since the firm is using different salts as a source for chloride e.g. Chloride will be delivered by Calcium chloride, sodium chloride and potassium chloride.
17.	Bio -lyte plus powder	EEC decided to defer the application for enlistment due to following reasons: The applied product contains Potassium Bicarbonate which is added in the list of common molecules.
18.	Clint Sachet	EEC decided to defer the application for enlistment for the following reasons: Justify the dose of Cranberry extract i.e. 20mg.
19.	Clint plus Sachet	EEC decided to defer the application for enlistment for the following reasons: Justify the dose of Cranberry extract i.e. 2470mg.
20.	Carver sachet	EEC decided to defer the application for enlistment for the following reasons: Justify the use of two different forms (herbal root powder and extract) of same ingredient i.e. Glycyrrhiza glabara.
21.	KalciD tablet	EEC decided to defer the application due to following reasons: Provide monograph of Coral calcium or otherwise revise the form-3. Brand name needs to be changed.
<b>M/s.Woodward Herbal Laboratories (Pvt) Ltd. (E. No. 00969)</b> <b>Plot no. 57-58, Sector 23, Korangi Industrial Area, Karachi</b>		
22.	MOVEGESIC ANALGESIC GEL	EEC decided to defer the application for enlistment for change of brand name.
<b>M/s Nutrevo Health Care,</b> <b>Khewat No. 438, Khatauni No. 452, Khasra No. 819, 14-Km Adyala Road, Rawalpindi. (E.NO.1124)</b>		
23.	Zeptize Syrup	EEC decided to defer the application for enlistment and to give final opportunity for the provision of: <ul style="list-style-type: none"> <li>monographs of all ingredients in exact form (Extract/oil) in which it is being used in the formulation, accordingly revise Form-3 where required.</li> </ul>
24.	Mr. Boost Capsule	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies since the firm did not provided the requisite documents and provided alternate names are not inline with EEC policy: <ul style="list-style-type: none"> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>Provide composition of marketed product as per checklist of form-3.</li> <li>Monographs of Horny goat weed extract, Tongkat Ali Ext. and Damiana leaf Ext. are required, or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> </ul>
25.	Slim Care Capsule	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
26.	Revoghol Sachet	EEC decided to defer the application for enlistment and to give final opportunity for the provision of monograph of Glucomannan (USP).
<b>M/s Legacy Pharmaceutical (Pvt) Ltd</b>		

S.No (1)	Brand name (2)	Decision (3)
<b>Plot 111-A, Industrial Estate, Hayatabad, Peshawar. (E.NO.00275)</b>		
27.	APRICARE 500MG CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning of specifications (USP/BP etc.) active ingredient.</li> <li>Provide monographs of Amygdalin (B17) or otherwise provide validation data of In-house testing method for both API(s) and Finished Product.</li> <li>Provide source of Amygdalin (B17).</li> <li>Testing specifications of Raw Material and Finished Products <ol style="list-style-type: none"> <li>Identity, Purity and strength</li> <li>Acceptable limits, ranges and criteria</li> <li>Testing procedures and methodology.</li> <li>Certificate of Analysis (COA)</li> </ol> </li> </ul>
28.	LESSCHOL500MG CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: <ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning of specifications (USP/BP etc.) active ingredient.</li> <li>Provide monograph of beta-sitosterol or otherwise provide validation data of In-house testing method for both API(s) and Finished Product.</li> <li>Testing specifications of Raw Material and Finished Products <ol style="list-style-type: none"> <li>Identity, Purity and strength</li> <li>Acceptable limits, ranges and criteria</li> <li>Testing procedures and methodology.</li> <li>Certificate of Analysis (COA)</li> </ol> </li> </ul> <p>The provided following three alternate brand names:</p> <ol style="list-style-type: none"> <li>Low Chol 500mg Capsule</li> <li>Nar Chol500mg Capsule</li> <li>Che Chol500mg Capsule</li> </ol>
29.	VIGAMOR CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
30.	LEGICRAN-C SACHET	EEC decided to defer the application for enlistment and to give final opportunity for the provision of differential fee of Rs:250/-.
31.	LEGICRAN PLUS SACHET	EEC decided to defer the application for enlistment and to give final opportunity for the provision of differential fee of Rs:250/-.
32.	CARDIO PRO SACHET	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: <ul style="list-style-type: none"> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name. (Since the provided names are not in line with EEC policy.)</li> <li>Justify the role of D-Ribose as active ingredient, as it doesn't cover under the definition of Health Product of SRO 412(I)/2014.</li> </ul>
<b>M/s. SHMZ Lab &amp; Pharmaceuticals (Pvt) Ltd., 101-Sundar Industrial Estate, Lahore. (E.NO.00231)</b>		
33.	SHMZ's CHEWLAC CHEWABLE TABLET	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>Verification of Probiotic Tablet manufacturing facility is required.</li> <li>Form-3 needs to be revised w.r.t. mentioning of specifications and strain of microorganism used in formulation.</li> <li>Monograph of strain microorganism is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> <li>Provide stability data of applied probiotic formulation in chewable tablet dosage form.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
34.	SHMZ's FLORA-B CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Capsule manufacturing facility is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of Saccharomyces boulardii is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
35.	SHMZ's INULAC CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Capsule manufacturing facility is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of microorganism used in formulation.</li> <li>• Provide strengths of Lactobacillus paracasei as CFU per capsule.</li> <li>• Monograph of Lactobacillus paracasei is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
36.	SHMZ's MULTIPRO CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Capsule manufacturing facility is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of microorganism used in formulation.</li> <li>• Monograph of all strains of microorganisms are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
37.	SHMZ's RHINOLAC CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Capsule manufacturing facility is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of microorganism used in formulation.</li> <li>• Monograph of strain microorganism is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
38.	SHMZ's BeceLac Sachet	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
39.	SHMZ's COLONICE SACHET	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
40.	SHMZ's ECOPRO SACHET	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
41.	SHMZ's FLORA-B SACHET	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of Saccharomyces boulardii is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
42.	SHMZ's FloraCran Sachet	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of strains and specifications of strains being used in the formulation.</li> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		strains used in formulation and method for identification of contaminant and pathogenic micro-organism).
43.	SHMZ's GastoPro Sachet	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Convert strength of each ingredient from “%” to “cfu/g”.</li> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
44.	SHMZ's GutPro Sachet	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
45.	SHMZ's LactoPro Sachet	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Sachet manufacturing facility is required.</li> <li>• Weight of each sachet in grams is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
46.	SHMZ's CLARUS CAPSULE Hair, Skin & Nails Formula	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Verification of Probiotic Capsule manufacturing facility is required.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>• Monograph of Sacchamomyces Cerevisiae Iis required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>• Provide monograph of Hydrolyzed Keratin (USP).</li> <li>• Mention salt of Selenium on form-3.</li> <li>• Provide Specifications and testing methods like Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Provide testing specifications of Raw Material and Finished Products as per checklist of Form-3               <ol style="list-style-type: none"> <li>Identity, Purity and strength</li> <li>Acceptable limits, ranges and criteria</li> <li>Testing procedures and methodology.</li> <li>Certificate of Analysis (COA)</li> </ol> </li> <li>Justify the role of hydrolyzed keratin as health product under SRO 412(I)/2014.</li> </ul>
47.	SHMZ's GUDBAC DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Verification of Probiotic Drops manufacturing facility is required.</li> <li>Form-3 needs to be revised w.r.t. mentioning of specifications and strain of each microorganism used in formulation.</li> <li>Strength of each ingredient is given as 0.5CFU per 5ml which needs clarification.</li> <li>Monograph of all strains of are required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism)</li> </ul>
48.	SHMZ's LACOSOL-B SUSPENSION	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Verification of Probiotic Suspension manufacturing facility is required.</li> <li>Form-3 needs to be revised w.r.t. mentioning of specifications and strain of microorganism used in formulation.</li> <li>Revise strength of probiotic mentioning CFU per unit delivery volume.</li> <li>Monograph of strain microorganism is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
49.	SHMZ's PROBICOL DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Verification of Probiotic Drops manufacturing facility is required.</li> <li>Revise strength of active ingredient per cfu/ml.</li> <li>Form-3 needs to be revised w.r.t. mentioning of specifications and strain of microorganism used in formulation.</li> <li>Revise strength of probiotic mentioning CFU per unit delivery volume.</li> <li>Monograph of strain microorganism is required or otherwise provide validation data of In-house testing method for both API and Finished Product.</li> <li>Finished product specifications and testing methods (Identification, Verification and Enumeration of specific strains used in formulation and method for identification of contaminant and pathogenic micro-organism).</li> </ul>
50.	SHMZ's MAXCOOL LOZENGES (ORANGE FLAVOR)	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</p>
51.	SHMZ's KOFISIL LOZENGES (LEMON FLAVOR)	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Provided monographs are general monographs having no methods details. Therefore, provide Monograph of all ingredients their extract form Except Adhatoda Vasica Extract (Malabur Nut Tree Leaf Extract).</li> </ul>
52.	SHMZ's KOF SIL LOZENGES (MINT FLAVOR)	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provided monographs are general monographs having no methods details. Therefore, provide Monograph of all ingredients their extract form Except Adhatoda Vasica Extract (Malabur Nut Tree Leaf Extract).</li> </ul>
53.	SHMZ's KOF SIL LOZENGES (ORANGE FLAVOR)	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provided monographs are general monographs having no methods details. Therefore, provide Monograph of all ingredients their extract form Except Adhatoda Vasica Extract (Malabur Nut Tree Leaf Extract).</li> </ul>
54.	SHMZ's KOF SIL LOZENGES (STRAWBERRY FLAVOR)	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provided monographs are general monographs having no methods details. Therefore, provide Monograph of all ingredients their extract form Except Adhatoda Vasica Extract (Malabur Nut Tree Leaf Extract).</li> </ul>
55.	SHMZ's PATHADONE DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Provide All undertakings duly signed and stamped by the owner/ CEO of the firm.</li> <li>• The label claimed strength of Vitamin-A is exceeding RDA i.e. 10,000IU, need clarification.</li> </ul>
56.	SHMZ's VITANE-AED DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</p>
57.	SHMZ's CALVIT-D DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Provide All undertakings duly signed and stamped by the owner/ CEO of the firm.</li> </ul>
58.	SHMZ's PATHADONE-D DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Provide All undertakings duly signed and stamped by the owner/ CEO of the firm.</li> </ul>
59.	SHMZ's PDA-OMEGA DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Application for enlistment (Form-3) is unsigned and unstamped.</li> <li>• All undertakings are unsigned and unstamped.</li> </ul>
60.	SHMZ's ORAVIT DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents:</p> <ul style="list-style-type: none"> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Provide All undertakings duly signed and stamped by the owner/ CEO of the firm.</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
61.	SHMZ's VITANE-D DROPS	EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents: <ul style="list-style-type: none"> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Provide All undertakings duly signed and stamped by the owner/ CEO of the firm.</li> </ul>
62.	SHMZ's VITANE-M DROPS	EEC decided to defer the application for enlistment and to give final opportunity for submission of following documents: <ul style="list-style-type: none"> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Provide revised form-3 duly signed by the owner of the firm.</li> <li>• Provide All undertakings duly signed and stamped by the owner/ CEO of the firm.</li> </ul>
<p align="center"><b>M/s Rose Homeo Research Laboratories, Plot No. 75-78, Small Industrial Estate, Sheikhabad, Takhtbhi Road, Charsadda. (E.NO.00932)</b></p>		
63.	Rose Homeo's Femafit Drops	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Provide Evidence of fee submission duly endorsed by statistical officer.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
64.	Rose Homeo's FIBRO CYST DROPS	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Evidence of fee submission is required.</li> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
65.	Rose Homeo's Gout Cure drops	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
66.	Rose Homeo's GALL - B – STONE	EEC decided to defer the application for enlistment and to give final opportunity to provide following documents: <ul style="list-style-type: none"> <li>• Evidence of fee submission is required duly endorsed by the Statistical officer of DRAP.</li> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Mention specification (EHPI, GHP, etc.) of each ingredient.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
67.	Rose Homeo's NATRUM ARS DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>Mention specification (EHPI, GHP, etc.) of each ingredient.</li> <li>Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
68.	Rose Homeo's Alfa Gold Syrup	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>Give safety profile of product as it contains toxic ingredient "Kali ars 2x" as preparations of toxic plants below 6x cannot be prepared.</li> <li>Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
69.	Rose Homeo's DYROL SYRUP	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
70.	Rose Homeo's H B PAIN DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>Mention specification (EHPI, GHP, etc.) of each ingredient.</li> <li>Evidence of fee submission is required duly endorsed by Statistical officer of DRAP.</li> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>Monograph of Cimicifuga racemose is missing</li> <li>Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
71.	Rose Homeo's ASHOKA SYRUP	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Evidence of fee submission is required duly endorsed by the statistical officer of DRAP.</li> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> <li>• Submit the evidence stating that the source of sepia 3x preparation should be free from salmonella, E.Coli and TSE contamination.</li> </ul>
72.	Rose Homeo's Ferrum - Plus SYRUP	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Form-3 needs to be revised w.r.t. mentioning strengths (w/vol or vol/vol) of all active ingredients.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
73.	Rose Homeo's FLATUNIL SYRUP	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Brand name needs to be changed.</li> <li>• Form-3 needs to be revised w.r.t. mentioning strengths (w/vol or vol/vol) of all active ingredients and mention potencies of "Arg - Net(GHP) and Lyco (GHP)".</li> <li>• Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
74.	Rose Homeo's SAW PALMETTO DROPS	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Form-3 needs to be revised w.r.t. mentioning specifications and strengths (w/vol or vol/vol) of all active ingredients.</li> <li>• Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>• Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
75.	Rose Homeo's ANTIPYRINE SYRUP	<p>EEC decided to defer the application for enlistment and to give final opportunity to provide following documents:</p> <ul style="list-style-type: none"> <li>• Provide the dose of active ingredients per unit delivery volume is missing in revised form-3 "each 5ml contains or each 10ml contains etc."</li> <li>• Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Form-3 needs to be revised w.r.t. mentioning strengths (w/vol or vol/vol) of all active ingredients and potency of “Bell (PHP), Ipecac (PHP) and Ferrum Phos (BHP)”.</li> <li>Form-3 needs to be revised w.r.t. mentioning of complete name of ingredients as per monograph.</li> <li>Since the product is a homeopathic combination therefore requirements laid down in para 2 of notification vide F.No.04-02/2017-DD(H&amp;OTC) dated 21-04-2020 needs to be fulfilled.</li> </ul>
<b>M/s Faisons-Meilleur Pharmaceuticals International (Pvt) Ltd., 28 km Ferozepur Road, Lahore (Nutraceutical). (E.NO.00545)</b>		
76.	Gold Feed Dry Powder	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
77.	Aminophyl Oral Liquid	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
78.	Diro-Vet Oral Liquid	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: <ul style="list-style-type: none"> <li>Application for enlistment (Form-3) needs to be revised w.r.t. mentioning the name of owner of the firm.</li> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>Provide monographs of Quercus robur extract and Origanum vulgare extract in extract form in which it is being used in the formulation, accordingly revise Form-3 where required.</li> <li>Justify the use of sorbitol, glycerine and Monopropylene glycol as active ingredient under SRO 412(I)/2014.</li> </ul>
79.	Garli Power Oral Liquid	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: <ul style="list-style-type: none"> <li>Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name.</li> <li>Provide official monograph of all ingredients in their extract form or otherwise provide validation data of In-house testing method for both Raw Material(s) and Finished Product.</li> </ul>
80.	Calcium Power Oral Liquid	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
81.	Coryza Cure Oral Liquid	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
82.	Stress Free Oral Liquid	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
<b>M/s MSK Cosmo &amp; Nutraceuticals, 5-KM, Lahore Road, Near Sialkot Bypass, Gujranwala. (E.NO.00975)</b>		
83.	Conciver capsule	EEC decided to defer the application for enlistment and to give final opportunity to provide monograph of Horny goat weed Extract The firm proposed following three alternate brand names: Zelus Trilus Eletor
84.	ASTOCID CAPSULES:	EEC decide to defer the the application for enlistment and to give final opportunity to provide monograph of all ingredients alongwith justify the use of “Oils” in Hard Gelatin Capsule.
<b>M/S Nurture Pharma Khasra No. 964, 6-Km, Off Raiwind Manga Road, Lahore (E. No. 01127)</b>		
85.	Nurture’s Fernur Sachet	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiency: <ul style="list-style-type: none"> <li>Provide monograph of Iron (as liposomal) and revise form-3 in the light of monograph submitted.</li> </ul> Provide undertaking
86.	Nurture’s Vicsnur Balm	EEC decided to defer the application for enlistment and to give final opportunity for the provision monograph of Cajuput oil.

S.No (1)	Brand name (2)	Decision (3)
87.	Nurture's Omagee Capsule	EEC decided to defer the application and to give final opportunity for the fulfillment of following deficiency <ul style="list-style-type: none"> <li>Mention additives and/or techniques used to Cod Liver Oil and fish oil (Omega-3 fatty acid) in capsule dosage form as part of its manufacturing process and master formula.</li> </ul> The firm proposed Onur Capsule as alternate brand name for Omagee Capsule.
<b>M/s Rax Laboratories, Lahore (E. No.277)</b> <b>21-KM, Ferozpur Road, Lahore</b>		
88.	RAX's COUGH SYRUP	Deferred with final opportunity for change of brand name
89.	RAX's FAIRAX CREAM	Deferred with final opportunity for change of brand name
90.	RAX's ALOPRAX LOTION	Deferred with final opportunity for change of brand name
91.	RAX's BREASTORAX LOTION	Deferred with final opportunity for change of brand name
92.	RAX's DENTAL LOTION	Deferred with final opportunity for change of brand name
93.	RAX's ITCHIRAX LOTION	Deferred with final opportunity for change of brand name
94.	RAX's FAIRAX TABLET	Deferred with final opportunity for change of brand name
95.	RAX's HYPERAX TABLET	Deferred with final opportunity for change of brand name
96.	RAX's HICHORAX TABLET	Deferred with final opportunity for change of brand name
97.	RAX's SPERMATORAX-M TABLET	Deferred with final opportunity for: Strength of strychnine to be rationalized. Brand name to be change.
98.	RAX's Antipyrinum Ø	Deferred with final opportunity for change of brand name
<b>Paul Brooks Homoeo Labs, Karachi</b>		
99.	Paul Brooks Tulsitux Cough Syrup	Deferred with final opportunity for change of brand name
100.	Paul Brooks Hepatogen Syrup	Deferred with final opportunity for change of brand name
101.	Paul Brooks Rheumax Red Oil	Deferred with final opportunity or change of brand name
102.	Paul Brooks STERILE RUTA EYE DROPS	Deferred with final opportunity for verification of sterile facility for preparation of eye drops
103.	Paul Brooks UP-2-HEMA ORAL LIQUID	Deferred with final opportunity for change of brand name
104.	Paul Brooks BEMAX SYRUP	Deferred with final opportunity for change of brand name
105.	Paul Brooks STERILE OPTI DRY EYE RELIEF DROPS	Deferred with final opportunity for Verification of availability of sterile facility for the preparation of eye drops
106.	Paul Brooks GASTROLIET TABLETS	Deferred with final opportunity for change of brand name
107.	Paul Brooks BEMAX ORAL LIQUID	Deferred with final opportunity for change of brand name
108.	Paul Brooks FERROTON FORTE CAPSULES	Deferred with final opportunity for change of brand name
109.	Paul Brooks CALCIWIN CHILDREN DROPS	Deferred with final opportunity for change of brand name
110.	Paul Brooks STERILE OPTI VISION SUPPORT EYE DROPS	Deferred with final opportunity for verification of sterile facility for preparation of eye drops
111.	Paul Brooks STERILE OPTI ALLERGY RELIEF EYE DROPS	Deferred with final opportunity for verification of sterile facility for preparation of eye drops
112.	Paul Brooks HEPAFORT SYRUP	Deferred with final opportunity for change of brand name

S.No (1)	Brand name (2)	Decision (3)
113.	Paul Brooks LEUCOGEN SYRUP	Deferred with final opportunity for change of brand name
114.	Paul Brooks SYMPHYTUM CREAM	Deferred with final opportunity for Safety profile of symphytum mother tincture for topical use
115.	Paul Brooks SAW PROSTA TABLETS	Deferred with final opportunity for change of brand name
116.	Paul Brooks LEUCOGEN SACHET	Deferred with final opportunity for change of brand name
117.	Paul Brooks ARNICA BRAIN TONIC	Deferred with final opportunity for change of brand name
118.	Paul Brooks IMSUKOON CAPSULES	Deferred with final opportunity for change of brand name
119.	Paul Brooks DIABETES CURE COURSE Capsule	Deferred with final opportunity for verification of the radio active ingredient
120.	Paul Brooks CALENDULA MEDICATED LOTION	Deferred with final opportunity for change of brand name
<b>M/s Salbion Health Sciences, 23km, Sheikhpura Road, Lahore (89M)</b>		
121.	Salbion's Slimmy Sachet	Deferred for final opportunity for change of brand name.
<b>Adcok Pharmaceutical (Pvt) Ltd, Lahore</b>		
122.	Dvitmax Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The firm uses herbs in crude form</li> <li>• Confirmation of herbal syrup section is required</li> </ul>
123.	Gincid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The firm uses herbs in crude form</li> <li>• Confirmation of herbal syrup section is required</li> </ul>
124.	Hacksol Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The firm uses herbs in crude form</li> <li>• Confirmation of herbal syrup section is required</li> </ul>
<b>Ali's Pakistan, Lahore</b>		
125.	Ali'S Ors Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Asfar Healthcare, Kasur</b>		
126.	Polycon Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
127.	Heptasil Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• The applied formulation contains N-Acetyl cysteine which is in the list of common molecule and deferred till the finalization of common molecule list</li> </ul>



S.No (1)	Brand name (2)	Decision (3)
128.	Glu Fig Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Stamped form 3 is required</li> <li>• Brand name needs to be changed</li> </ul>
129.	Ovum Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• The applied formulation contains N-Acetyl cysteine which is in the list of common molecule and deferred till the finalization of common molecule list</li> </ul>
130.	Ferrowill Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Stamped form 3 is required</li> <li>• Brand name needs to be changed</li> </ul>
131.	Di-Stone Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Firm uses herbs in crude form</li> <li>• confirmation of herbal syrup section is required</li> <li>• Brand name needs to be changed</li> </ul>
<b>Aulton Nutraceuticals, Hattar</b>		
132.	Olsuna Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
133.	Multivit Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
134.	Leofert Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
135.	Cac Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
136.	Natalavit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since

S.No (1)	Brand name (2)	Decision (3)
		computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Bio Life Enterprises Nutraceuticals, Rawalpindi</b>		
137.	Forcal Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Undertaking regarding content and brand name is required</li> <li>• Brand name needs to be changed</li> </ul>
<b>Bion Life Sciences, Lahore</b>		
138.	Biovit-M Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
139.	D'Vito Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
140.	D'Vito-Ad Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
141.	D'Vito-Os Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Calgan Phyto Pharma Pvt Ltd, Lahore</b>		
142.	Armax Liquid Herbal Ext	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
143.	Apitol Liquid Herbal Ext	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
144.	Dicaine Liquid Herbal Ext	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
145.	Hensa Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
146.	Carti Gel	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since

S.No (1)	Brand name (2)	Decision (3)
		computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
147.	Tryker Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> <li>• Signed form 3 is required</li> </ul>
148.	Super Vitamin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> <li>• Evidence of R&amp;I receiving is required</li> <li>• signed form 3 is required</li> </ul>
149.	Vitamix Liquid Herbal Ext	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> </ul> Brand name needs to be changed
150.	Pepzid Herbal Ext	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
151.	Ground Ivy Leaf	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
152.	Bonwin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> <li>• Revised form 3 w.r.t specification is required</li> <li>• Specify the quantities of iodine,Manganese,Potassium and Boron in the formulation</li> <li>• Monograph of Real fruit juice extract is required</li> </ul>
153.	Ipical Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Monograph of red calcium algae is required</li> <li>• Monograph of Real fruit juice blend is required along with justification of its use as a Nutraceutical product</li> <li>• Brand name needs to be changed</li> </ul>
154.	Winmin Ad Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
155.	Glucoplex Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>The applied formulation contains Glucosamine, Chondroitin sulphate Hyaluronic acid which are in the list of common molecule and deferred till the finalization of common molecule list</li> <li>Revised form 3 w.r.t specification is required</li> </ul>
156.	Nucid Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
157.	Q-Zim 10 Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>
158.	Etine Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Revised form 3 w.r.t specification is required</li> <li>Monograph of L-carnitine is required</li> </ul>
159.	Manex Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Revised form 3 w.r.t specification is required</li> <li>Monograph of chelated iron and Asparagus racemosus are required</li> </ul>
160.	Unical Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> <li>Revised form 3 w.r.t specification is required</li> <li>Specify the quantities of iodine, Manganese, Potassium and Boron in the formulation</li> <li>Signed form 3 is required</li> </ul>
161.	Myoplex Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>
162.	Kiddycol Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Confirmation of herbal liquid section</li> </ul>
163.	Vitamix Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>
164.	Myofocid Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>
165.	Unigex Liquid Herbal Ext	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
166.	Carti Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> <li>The applied formulation contains Chondrition,Glucosamine and capsaicin which are in the list of common molecule and deferred till the finalization of common molecule list</li> </ul>
167.	Irose F Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>
<b>Cidex Laboratories, Peshawar</b>		
168.	Oricom-F Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains Iron polymaltose which is in the list of common molecule and deferred till the finalization of common molecule</li> <li>Brand name needs to be changed</li> </ul>
169.	Provesta-Ed Capsule	The application is already disposed off in 96 <sup>th</sup> EEC meeting
170.	Xcitor Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Monograph of Pausinystalis yohimbe extract is required</li> </ul>
171.	Osto-Click Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
<b>Dolphin Laboratories, Lahore</b>		
172.	Dolphin Ors Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Evergreen Pharmaceuticals, Lahore</b>		
173.	Punjab Dairy Premix Powder	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Revised Form 3 w.r.t specification is required</li> </ul>
<b>Gerishon International, Karachi</b>		
174.	Ointment Fissure Forte	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>confirmation of herbal ointment section</li> </ul>
<b>Glorious Laboratories, Islamabad</b>		
175.	Ip-6 Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Monograph of Inositol hexaphosphate (from calcium Magnesium phytate) is required</li> <li>Brand name needs to be changed</li> </ul>
176.	Multiday M Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Evidence of R&amp;I receiving is required</li> <li>Brand name needs to be changed</li> </ul>
177.	Calmi D Tablet	EEC decided to defer the application for enlistment due to following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Monograph of Red calcium algae is required</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
178.	Plant Cough Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
<b>Greektec Nutraceutical, Karachi</b>		
179.	Knee Flex Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• The applied formulation contains Hyaluronic acid and glucosamine which is in the list of common molecule and deferred till the finalization of common molecule</li> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
180.	Pynocare Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
181.	Fairlite Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Evidence of R&amp;I receiving is required</li> <li>• Brand name needs to be changed</li> </ul>
182.	Makcal Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
183.	Makvit Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
184.	Makcal Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Revised form 3 w.r.t specification is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regarding stability studies is required</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
185.	Dulkoff Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant</p>



S.No (1)	Brand name (2)	Decision (3)
		product application to check its status whether it has been disposed of or otherwise.
186.	Makron Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
187.	Zinckid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
188.	Makron Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Revised form 3 w.r.t specification is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regarding stability studies is required</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
189.	Calcio Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Revised form 3 w.r.t specification is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regarding stability studies is required</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
190.	Mylax Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Hinucon, Karachi</b>		
191.	Profect Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
192.	Profect Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No (1)	Brand name (2)	Decision (3)
		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Hiranis Pharmaceuticals (Pvt) Limited, Karachi</b>		
193.	Feroblis Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of Zinc picolinate is required</li> <li>• Brand name needs to be changed</li> </ul>
194.	Feroblis Ds Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of Zinc picolinate is required</li> <li>• Brand name needs to be changed</li> </ul>
195.	Feday Plus Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
196.	Cadik Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
197.	Feday Plus Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking notarized regarding content and brand name is required</li> </ul>
198.	Feroblis Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monograph of Zinc picolinate is required</li> <li>• Brand name needs to be changed</li> </ul>
<b>Hizat Nutraceutical Industries, Peshawar</b>		
199.	Calzat Plus Suspensionn	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Izfaar Nutraceutical Industries, Lahore</b>		
200.	Burnoi Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> <li>• Justify the role of Sulphur as nutraceutical ingredient in the formulation</li> </ul>
201.	Burnof Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> <li>• Justify the role of Sulphur as nutraceutical ingredient in the formulation</li> </ul>

S.No (1)	Brand name (2)	Decision (3)
202.	Acne-Nil Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation contains Salicylic acid which is registered as a drug</li> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> </ul>
203.	Paingo Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> </ul>
204.	Glow White Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation is intended for cosmetic purpose</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> </ul>
205.	Hr Cream Cream	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation is intended for cosmetic purpose</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> </ul>
206.	Pure White Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
207.	Izfaar Castor Oil Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
208.	Izfaar Glycerin Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No (1)	Brand name (2)	Decision (3)
209.	Droplex Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
210.	Hi-Bone Plus Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
211.	Hi-Grow Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
212.	Retifol Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
213.	Buildcal Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> <li>• Monograph of coral calcium is required</li> </ul>
214.	Paedi Aqua Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• The applied formulation contains ORS formulation which is common molecule and deferred till the finalization of common molecule</li> <li>• Brand name needs to be changed</li> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking notarized regarding content and brand name is required</li> <li>• Undertaking regrading stability studies is required</li> </ul>
<b>King Camco Pharma Nutraceutical, Lahore</b>		
215.	Malo-Cid Syrup	EEC decided to defer the application for enlistment due to following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
216.	Tlgen Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Undertaking notarized regarding content and brand name is required</li> </ul>
217.	Ferifer Malt Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>The applied formulation contains Iron polymaltose which is common molecule and deferred till the finalization of common molecule</li> <li>Brand name needs to be changed</li> </ul>
<b>Legacy Pharmaceuticals, Peshawar</b>		
218.	Legicran C Sachet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
219.	Legicran C Plus Sachet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
220.	Legore-Plus Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Differential fee is required in case of nutraceutical product as product is applied for herbal product</li> <li>Firm uses herbs in crude form</li> <li>confirmation of herbal liquid section</li> </ul>
221.	Kuf Out Plus Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Undertaking regrading content and brand name is required</li> <li>Brand name needs to be changed</li> </ul>
222.	Lithos Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>The applied formulation contains Potassium citrate which is common molecule and deferred till the finalization of common molecule</li> <li>Properly filled signed and stamped form 3 is required</li> <li>Undertaking regrading content and brand name is required</li> <li>Brand name needs to be changed</li> </ul>
223.	Aibas Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> <li>Differential fee is required as product is applied for nutraceutical product</li> <li>Properly filled signed and stamped form 3 is required</li> <li>Undertaking regrading content and brand name is required</li> </ul>
224.	Vigamor Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent</p>

S.No (1)	Brand name (2)	Decision (3)
		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
225.	Kuf Out Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking regrading content and brand name is required</li> <li>• Differential fee is required As fee applied for herbal product</li> <li>• Brand name needs to be changed</li> </ul>
226.	Legor Plus Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• firm uses herbs along with nutraceutical ingredients</li> <li>• Undertaking regrading content and brand name is required</li> <li>• Differential fee is required As fee applied for herbal product</li> <li>• Brand name needs to be changed</li> </ul>
227.	Ezy Bul Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
228.	Lagicran-C Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
229.	Lagicran Plus Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Mint Pharmaceutical Pvt Ltd, Lahore</b>		
230.	Smokezy Lozenge	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
231.	Hazamasan Lozenge	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
232.	Embifer Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
<b>MSG Nutraceuticals, Islamabad</b>		
233.	Neuad Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Confirmation of Herbal syrup section</li> </ul>
234.	Synol Nasal Spray	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>The applied formulation contains Capsicum extract as nasal spray, justify its role as a nutraceutical product</li> </ul>
235.	Logical Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
236.	Irofix Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
237.	Maarit M Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> </ul>
238.	Big Vits Plus Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
239.	Api Rose Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> </ul>
240.	Menoria Care Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Confirmation of Herbal syrup section</li> </ul>
241.	Lenoria Care Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> <li>Firm uses herbs in crude form</li> <li>Confirmation of Herbal syrup section</li> </ul>
242.	Maarit M Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Properly filled signed and stamped form 3 is required</li> <li>Brand name needs to be changed</li> </ul>
<b>MSK Cosmo &amp; Nutraceutical, Gujranwala</b>		
243.	Kal.Plus Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Brand name needs to be changed</li> <li>Undertaking regrading content and brand name is required</li> </ul>
244.	Orich Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Undertaking regrading content and brand name is required</li> </ul>
245.	Orich Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Undertaking regrading content and brand name is required</li> </ul>
246.	M.Wid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>Undertaking regrading content and brand name is required</li> </ul>
247.	Ginostol Sachet	EEC decided to defer the application for enlistment due to following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Undertaking regrading content and brand name is required</li> </ul>
<b>Nutrifactor Laboratories (Pvt) Ltd, Faisalabad</b>		
248.	L-Arginine Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
249.	Nutri Collagen Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
250.	C-Boost Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
251.	Extra-D Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Nutris Laboratories, Lahore</b>		
252.	Cough-Q Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
<b>Oasis Pharma, Lahore</b>		
253.	Liver-N Food Supplement	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Confirmation of food supplement/nutritional section is required.</li> </ul>
<b>Paksons Neutro, Kabirwala</b>		
254.	Mekfit-T Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
255.	Tain-D Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
256.	Ocolin Tablet	EEC decided to defer the application for enlistment due to following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Monograph of Choline-L-Bitartrate is required</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
257.	Dekif-R Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
258.	Aynaw-M Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> </ul>
259.	Zaum-3 Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> <li>• Evidence of R&amp;I receiving is required</li> </ul>
<b>Pharm Evo, karachi</b>		
260.	Ad-D Chewable 2000Iu Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
261.	Ad-D Chewable 10000Iu Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Sidaz health foods, Hyderabad</b>		
262.	Va-Plex Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Stamped form 3 is required</li> </ul>
263.	Zm-D Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Stamped form 3 is required</li> <li>• Brand name needs to be changed</li> </ul>
264.	Sk-D Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Stamped form 3 is required</li> </ul>
265.	Si-Gest Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Stamped form 3 is required</li> </ul>
266.	Haitone-M Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Evidence of R&amp;I receiving is required</li> <li>• Stamped form 3 is required</li> </ul>
<b>Simbro HealthCare, Lahore</b>		
267.	Calsim Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
268.	Diabate Tablet	EEC decided to defer the application for enlistment due to following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Brand name needs to be changed</li> </ul>
269.	Rhusen Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Monographs of Senna folium extract, Rheum radix extract and vegetable charcoal exytract are required</li> </ul>
270.	Vel Don Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
271.	Pro-Life Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
272.	Preg-Vel Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
273.	Calcium-D Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
274.	Fav-Vit Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
275.	Hi-Life Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division

S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Vital Phyto Pharma (Pvt) Ltd, Rawalpindi</b>		
276.	Denhit Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>Wilshire Laboratories Pvt Ltd, Lahore</b>		
277.	Apperize Lozenges	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking regarding content and brand name is required</li> <li>• The applied formulation contains Ammonium chloride which is common molecule and deferred till the finalization of common molecule</li> </ul>
278.	Somnia Natural 2Mg Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking regarding content and brand name is required</li> <li>• The applied formulation contains Melatonin which is common molecule and deferred till the finalization of common molecule</li> </ul>
279.	Somnia Natural 5Mg Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking regarding content and brand name is required</li> <li>• The applied formulation contains Melatonin which is common molecule and deferred till the finalization of common molecule</li> </ul>
280.	K2M7 Shot Oral Liquid	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking regarding content and brand name is required</li> <li>• Clarification regarding facilities of oral liquid ampoule is required</li> </ul>
281.	Somnia Natural 3Mg Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> <li>• Properly filled signed and stamped form 3 is required</li> <li>• Undertaking regarding content and brand name is required</li> <li>• The applied formulation contains Melatonin which is common molecule and deferred till the finalization of common molecule</li> </ul>
<b>M/s Cherry Pharmaceutica Internatinal, 14-E, Ground Floor/Basement Punjab Cooperative Housing Society, Ghazi Road, Lahore agent of M/s Huvepharma SA, 34, Rue Jean Monnet – Zone Industrial d’Etriche – Segre – 49500 Segre-En-Anjou Bleu, France (E. No. 01074)</b>		
282.	Carnitol-L	Deferred due to following reasons: <ul style="list-style-type: none"> <li>• Application is not submitted on prescribed Form 5.</li> <li>• Clarification regarding the strength of each ingredient used in Plant extract and role of each active ingredient.</li> </ul>
<b>M/s Vetynex Pharma, located at 1.5-Km Defence Road, Off Ferozpur Road, Kahna Nau, Lahore agent of M/s Alphafacts Health Solutions BVBA, Industrieterrein Klein Gent Diamantstraat 8 B 101 2200 Herentals, Belgium (E. No. 01185)</b>		
283.	Alpha Haemofed Syrup	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> <li>• Fee should be submitted in accordance with the fee schedule notified vide no. F. 8-4/2018- H&amp;OTC/DRAP.</li> <li>• Clarification regarding the EN numbers in the formulation given in form 5</li> </ul>
284.	Alpha Stress Free Syrup	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Fee should be submitted in accordance with the fee schedule notified vide no. F. 8-4/2018- H&amp;OTC/DRAP.</li> <li>• Clarification regarding the EN and CoE numbers in the formulation given in form 5.</li> <li>• Brand name is not appropriate.</li> </ul>
285.	Alpha Pregafit Syrup	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Fee should be submitted in accordance with the fee schedule notified vide no. F. 8-4/2018- H&amp;OTC/DRAP.</li> <li>• Clarification regarding the EN and CoE numbers in the formulation given in form 5.</li> </ul>
286.	Alpha Phytocuff Syrup	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Fee should be submitted in accordance with the fee schedule notified vide no. F. 8-4/2018- H&amp;OTC/DRAP.</li> <li>• Clarification regarding the EN and CAS numbers in the formulation given in form 5.</li> </ul>
287.	Zealup Syrup	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Fee should be submitted in accordance with the fee schedule notified vide no. F. 8-4/2018- H&amp;OTC/DRAP.</li> <li>• Clarification regarding the EN numbers in the formulation given in form 5.</li> </ul>
<b>M/s. Nutralake Healthcare, Plot No. C-105, KDA Scheme No. 01, Off Karsaz Road, Karachi-Pakistan Principal manufacturer: M/s Essential Pharmaceutical, Corp. 1906 W. Holt Avenue Pomona, CA 91768 Dist: Los Angeles, USA (E. No. 00173)</b>		
288.	Strontium Tablet	Deferred as the formulation contains Glucosamine and chondroitin which are included in the list of common molecules.
289.	Synordy Tablet	Deferred since the formulation contains Glucosamine and chondroitin, which is included in the list of common molecules
<b>M/s SMS Corporation., located at the address 13-B, Block 6, P.E.C.H.S, Shahrah-e-Faisal, Karachi agent of M/s Limited Liability Company Pharmaceutical Plant "Biofarma", located at Building 37, Kyivska street, BilaTserkva, Kyiv region, Ukraine (E. No. 00981)</b>		
290.	Bifidumbacterin Vial	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Specific stain of probiotic is required.</li> <li>• Testing specification and characterization of probiotics is required.</li> <li>• Long term and accelerated stability studies according the requirement of Zone IV A is required.</li> <li>• Free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of Origin.</li> </ul>
291.	Subalin Vial	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Specific stain of probiotic is required.</li> <li>• Testing specification and characterization of probiotics is required.</li> <li>• Long term and accelerated stability studies according the requirement of Zone IV A is required.</li> <li>Free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of Origin.</li> </ul>
292.	Biosporin Vial	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Specific stain of probiotic is required.</li> <li>• Testing specification and characterization of probiotics is required.</li> <li>• Long term and accelerated stability studies according the requirement of Zone IV A is required.</li> <li>Free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of Origin.</li> </ul>



<b>S.No</b>	<b>Brand name</b>	<b>Decision</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>
<b>293.</b>	Subalin Sachet	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Specific stain of probiotic is required.</li> <li>• Testing specification and characterization of probiotics is required.</li> <li>• Long term and accelerated stability studies according the requirement of Zone IV A is required.</li> </ul> Free sale certificate issued by the regulatory body countersigned by the Embassy of Pakistan in the country of Origin.
<b>M/s SS Associates, located at the address, 8/10 Jail Road, Behind Nirrala Sweets, Lahore agent of M/s AIZ International CO., Ltd., 93/1034 G, Le Duc Tho Str, Ward. 6, Go Vap District HCM City, Vietnam [Principle Manufacturer M/s Anvet Pharma Joint Stock Company (Anvet Pharma JSC) Plot no. B2-19, Tan Dong Hiep B Industrial Park, Tan Dong Hiep Ward, Di An Binh, Duong, Vietnam] (E. No. 01012)</b>		
<b>294.</b>	Ascorbic-WS Powder	Deferred for Clarification regarding dosage form and ratio of active ingredient in the formulation.
<b>295.</b>	Toxyliq Oral Solution	Deferred as the for following reasons: <ul style="list-style-type: none"> <li>• The free sale certificate submitted does not depict that the said product is freely available in the country of origin.</li> </ul>
<b>296.</b>	Healthvet Liquid	Deferred for following reasons: <ul style="list-style-type: none"> <li>• The free sale certificate submitted does not depict that the said product is freely available in the country of origin.</li> </ul>
<b>M/s Nutra Zone health Care, Suite No. 1, Plot No. 58-C, 25th TauheedCommerical, DHA Phase-5, Karachi (Principal manufacturer M/s Thompson &amp; Capper Limited, 1-13 Hardwick Toad, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1PH, United Kingdom (E. No. 0067)</b>		
<b>297.</b>	CoffeeSlim Capsule	Deferred for change of brand name

  
 (Ayyaz Ahmad)

**Secretary, Enlistment Evaluation Committee**

# ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY.**

## MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYYY
2.								

## MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	<b>XYZ Tablet</b> Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's
2.					